View Item 

Show simple item record

Letter: lessons from the ‘real‐world’ entecavir therapy in chronic hepatitis B patients – authors’ reply
dc.contributor.authorAhn, J.
dc.contributor.authorNguyen, M. H.
dc.contributor.authorLim, J. K.
dc.contributor.authorLee, H. M.
dc.contributor.authorPan, C. Q.
dc.contributor.authorLok, A. S.
dc.date.accessioned2016-03-07T19:05:29Z
dc.date.available2017-06-01T16:55:24Zen
dc.date.issued2016-04
dc.identifier.citationAhn, J.; Nguyen, M. H.; Lim, J. K.; Lee, H. M.; Pan, C. Q.; Lok, A. S. (2016). "Letter: lessons from the ‘real‐world’ entecavir therapy in chronic hepatitis B patients – authors’ reply." Alimentary Pharmacology & Therapeutics 43(7): 847-848.
dc.identifier.issn0269-2813
dc.identifier.issn1365-2036
dc.identifier.urihttps://hdl.handle.net/2027.42/117480
dc.publisherWiley Periodicals, Inc.
dc.titleLetter: lessons from the ‘real‐world’ entecavir therapy in chronic hepatitis B patients – authors’ reply
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelOtolaryngology
dc.subject.hlbsecondlevelPharmacy and Pharmacology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/117480/1/apt13558.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/117480/2/apt13558_am.pdf
dc.identifier.doi10.1111/apt.13558
dc.identifier.sourceAlimentary Pharmacology & Therapeutics
dc.identifier.citedreferenceChang M‐L, Liaw Y‐F. Letter: lessons from the “real‐world” entecavir therapy in chronic hepatitis B patients. Aliment Pharmacol Ther 2016; 43: 846 – 7.
dc.identifier.citedreferenceLiu A, Ha N, Lin B, et al. Low hepatitis B envelope antigen seroconversion rate in chronic hepatitis B patients on long‐term entecavir 0.5 mg daily in routine clinical practice. Eur J Gastroenterol Hepatol 2013; 25: 338 – 43.
dc.identifier.citedreferenceYuen MF, Seto WK, Fung J, et al. Three years of continuous entecavir therapy in treatment‐naive chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety. Am J Gastroenterol 2011; 106: 1264 – 71.
dc.identifier.citedreferenceZoutendijk R, Reijnders JG, Zoulim F, et al. Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. Gut 2013; 62: 760 – 5.
dc.identifier.citedreferenceAhn J, Lee HM, Lim JK, et al. Entecavir safety and effectiveness in a national cohort of treatment‐naïve chronic hepatitis B patients in the US – the ENUMERATE study. Aliment Pharmacol Ther 2016; 43: 134 – 44.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
apt13558.pdf
Size:
78.22KB
Format:
PDF
View/Open
Name:
apt13558_am.pdf
Size:
71.13KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.